UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
(Amendment
No. 1)
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): December 17, 2009
BIOANALYTICAL
SYSTEMS, INC.
(Exact
name of registrant as specified in its charter)
Indiana
|
|
0-23357
|
|
35-1345024
|
(State
or other
jurisdiction
of
incorporation
or
organization)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification
No.)
|
2701 KENT AVENUE
WEST LAFAYETTE, INDIANA
|
|
47906-1382
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant's
telephone number, including area code: (765) 463-4527
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange
Act(17CFR240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange
Act(17CFR240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act(17CFR240.13e-4(c))
|
Item
5.02. Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.
On
November 12, 2009, Bioanalytical Systems, Inc. (the "Company") announced that
John B. Landis, Ph.D. was elected to the Company's Board of Directors ("Board")
and reported this information on the Company's Form 8-K dated November 18, 2009.
At the time of filing such Form 8-K, the Board committee(s) to which Dr. Landis
would be named had not yet been determined and approved by the Board. The
Company is filing this Form 8-K/A to report the Board committee assignments for
Dr. Landis.
On
December 17, 2009, the Board appointed Dr. Landis to serve on the Board's
Compensation Committee and Nomination Committee.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Bioanalytical
Systems, Inc.
|
|
|
|
Date:
December 23, 2009
|
By:
|
/s/
Michael R. Cox
|
|
|
Michael
R. Cox
|
|
|
Vice
President, Finance and Administration,
|
|
|
Chief
Financial Officer and
Treasurer
|